Source: European Parliament
Many patients who suffer from Alpha-1 antitrypsin deficiency face the challenges of late diagnosis, limited awareness of the disease and limited access to affordable treatment. The Commission has stated that the EU’s strategic objective for rare diseases is to improve patient access to diagnosis, information and care.
1 Does the Commission acknowledge that these problems should be addressed as a matter of priority?
2 What concrete measures does the Commissioner for Health and Food Safety intend to take to tackle these problems?